Cross-Vendor Reproducibility of Radiomics-based Machine Learning Models for Computer-aided Diagnosis
Chaudhary, Jatin, Jambor, Ivan, Aronen, Hannu, Ettala, Otto, Saunavaara, Jani, Boström, Peter, Heikkonen, Jukka, Kanth, Rajeev, Merisaari, Harri
–arXiv.org Artificial Intelligence
Background: The reproducibility of machine-learning models in prostate cancer detection across different MRI vendors remains a significant challenge. Methods: This study investigates Support Vector Machines (SVM) and Random Forest (RF) models trained on radiomic features extracted from T2-weighted MRI images using Pyradiomics and MRCradiomics libraries. Feature selection was performed using the maximum relevance minimum redundancy (MRMR) technique. We aimed to enhance clinical decision support through multimodal learning and feature fusion. Results: Our SVM model, utilizing combined features from Pyradiomics and MRCradiomics, achieved an AUC of 0.74 on the Multi-Improd dataset (Siemens scanner) but decreased to 0.60 on the Philips test set. The RF model showed similar trends, with notable robustness for models using Pyradiomics features alone (AUC of 0.78 on Philips). Conclusions: These findings demonstrate the potential of multimodal feature integration to improve the robustness and generalizability of machine-learning models for clinical decision support in prostate cancer detection. This study marks a significant step towards developing reliable AI-driven diagnostic tools that maintain efficacy across various imaging platforms. Keywords: Machine Learning Inter-Vendor Reproducibility Radiomics Prostate Cancer Diagnostic tools Model Reproducibility 1 Introduction Thinking about the transformative era of medical diagnostics with the integration of machine learning (ML) into cancer detection opens up a new oil reserve of possibilities.
arXiv.org Artificial Intelligence
Jul-25-2024
- Country:
- Europe
- Slovenia (0.04)
- Finland
- Southwest Finland > Turku (0.06)
- Northern Savo > Kuopio (0.04)
- Europe
- Genre:
- Research Report
- New Finding (1.00)
- Experimental Study (0.94)
- Research Report
- Industry:
- Health & Medicine > Therapeutic Area > Oncology > Prostate Cancer (0.95)
- Technology: